Our paper on Chemistry in Second Life is marked as "Highly Accessed" in Chemistry Central Journal - that's nice to discover http://www.journal.chemistryce...
The question is whether you can calculate standard deviation for fold change values if the groups you compare are not matched.
- Berci Mesko, MD
So you are considering the ratio of values derived from 2 unmatched populations, like testing 2 populations with different treatments? In that case I would use an ANOVA rather than working with the ratio... or did I miss something?
- Yann Abraham
One group of controls and one group of diseased patients.
- Berci Mesko, MD
Unfortunately, my Athens does not extend to NPG content :-( "Can web 2.0 reboot clinical trials?" Nature Biotechnology 27, 895 - 902 (2009) doi:10.1038/nbt1009-895 http://www.nature.com/nbt...
I can understand WP doesn't want to have an article on every John Smith in the world, but these endless notability battles are tedious. If you present at one conference are you notable? If you get one interview? "regarded as an important figure by peers" is not exactly a quantitative metric. Timo has a demonstrable body of work in many venues; that should be enough for notability. I was...
more...
- Richard Akerman
Just weighed in, it will certainly be kept.
- Berci Mesko, MD
My first post on the 23andMe blog... SNPwatch: Common Variants May Influence Glaucoma Risk in Individuals of African Descent - http://spittoon.23andme.com/2009...
The "news report" style can seem a little dull, but I guess I always have my own blog for less formal stuff...
- Shirley Wu
from twhirl
I found it very hard blogging for the AWS blog even though it's not quite as formal
- Deepak Singh
I always mention the Spittoon blog in all of my presentations that focus on how the public could get closer to personalized medicine or genomics.
- Berci Mesko, MD
"Examples of automated medical technologies given include health monitoring kiosks, automated X-rays, e-learning systems and surgical robots"
- Berci Mesko, MD
from Bookmarklet
Very interesting Berci - one of the issues I never understood about drug studies is how do you account for the fact that any drug with a common side effect will tip off the patient that they are definitely getting the real stuff and not a placebo - thus contributing to a higher expectation that it should work to alleviate symptoms.
- Jean-Claude Bradley
The placebo might have a small incidence of apparent side effects but if you take something like Lunesta the bad taste in your mouth will give you a definite sign that you have not taken the placebo.
- Jean-Claude Bradley
same story with recent stem cell trial - no difference with placebo. People believe in "new magic pill" and get "high" emotionally.
- Alexey
Thanks, Bill. We're really happy that is coming to Kingston. Poor kid will come just before winter, so we hope he stick around for longer, after the first snowstorm :-)
- Paulo Nuin
Way cool!!! So how are you going to react when he opens up Mendeley :)?
- Deepak Singh
Mendeley is currently block in the lab. He will have to prove capable of circumventing our firewall.
- Paulo Nuin
Googling "firewall circumvention for dummies"... ;)
- Ricardo Vidal
Watch your back Paulo, they're trying to get an insider to remove your top search result for "mendeley review" :P Sounds fun. Good luck Ricardo!
- Brian Krueger - LabSpaces
No, DTC genomics isn't medicine, and it doesn't matter how many times you insist it is. There remains a fundamental difference between information and the uses to which that information is put. Everyone else on the web seems to understand this. Berci, you provide a valuable service aggregating medicine related articles and you're one of my best filters/sources, but i do with your crank-filter were a little tighter sometimes.
- Mr. Gunn
Thank you, Mr. Gunn! Well, sometimes it happens. But I must admit I know Steve Murphy personally and he seriously affected my thoughts on personal genomics. He helped me a lot about how to become a clinical geneticist and in the vast majority of cases, I agree with his opinion. In terms of outcomes or consequences, DTC genomics should be considered medicine.
- Berci Mesko, MD
I want to make sure I understand your argument, because I'm sure it must be a little more subtle that what I get from reading his post. Are you saying that because someone might make a medical decision for themselves based on the data returned from somewhere like 23andme, it should be put in the same category as a medical diagnostic test, and regulated by requiring a doctor's order?
- Mr. Gunn
I couldn't have said it better. Yes, I think so, and I'm sure Steve thinks pretty the same. DTC is not just playing with fancy results and colorful graphs because people will make medical decisions based on these. And that is dangerous no matter how strongly these companies state these results shouldn't be used for medical decision-making.
- Berci Mesko, MD
Great, Graham. I hope you will make and share some notes. :)
- Berci Mesko, MD
Arse. I got side-tracked writing a comment on the PatientsLikeMe - ALS Forum and missed the first 30 mins of the 45 min event. Someone coughed most of the way through the last bit although David Gillikin came across clearly. Must make contact with him. Let's hope that our Krafty Librarian can provide a less ambiguous summary :-)
- Graham Steel
That is incredible, I remember a couple years ago it was predicted to happen around 2011, and Church estimated $100 by 2013. Looks like it will happen much faster, thanks for the update.
- Colby
from PeopleBrowsr
I am very skeptical of the cost. Does it include the cost of consumables, which don't have the same economies of scale. What about people, power and compute? In other words, this is NOT a fully loaded cost
- Deepak Singh
You're right, Deepak, this is not the full cost, just the cost of the sequencing itself.
- Berci Mesko, MD
As I thought. Would be nice if the folks talking about those numbers were clear about the costs not being fully loaded
- Deepak Singh
from IM
This is already sounding like TCO arguments over operating systems. Total Cost of Genome Ownership ... I guess companies like 23andMe would also argue that you need to factor in the cost of access to decent analysis tools. A raw string of ATCGs isn't much use to the average punter ...
- Andrew Perry
that's one step further down. I am still at the level of a run. Of course, with instruments, storage, downstream computing, etc, this adds up fast. For someone like 23andme, storage costs, analysis tools and web infrastructure will add up quickly
- Deepak Singh
from IM